Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company is headquartered in George Town, Grand Cayman and currently employs 57 full-time employees. The firm is primarily focused on developing mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal, neurodegenerative and metabolic diseases. The firm is engaged in developing its product pipelines, which include Elamipretide, SBT-20 and SBT-272.